top of page
Spikimm will be participating to Basel for the health.tech | global summit (March 3–5, 2026).
Paul GINESTE (CEO, SpikImm) — formerly EVP Clinical Development at Abivax — will be on-site and happy to connect with partners, investors, and industry peers.
Want to book a 1:1 meeting? Reach out at paul.gineste@spikimm.com
SpikImm, founded by Truffle Capital and Institut Pasteur develops SPK004, the most potent and long-acting anti-BK virus mAb to protect kidney transplant patients from severe complications caused by BKV (nephropathy, graft loss)
bottom of page